Milodistim (Amgen)

N/A

Report date: 2022/02/18 09:35:50

Base Information

Drug NameMilodistim (Amgen)
Drug Alias NamePixykinePlasmid Immunex yeast 321PIXY-321GM-CSF/IL-3
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionColony stimulating factor 3 receptor agonistsInterleukin-3 receptor subunit alpha modulators
TargetsColony stimulating factor 3 receptorInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsNeutropeniaThrombocytopenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmgen IncWyeth Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsNeutropeniaThrombocytopenia

Other Information

ATC CodeN/A
Related LinksKEGG